This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demeter, L. M.
Right arrow Articles by Reichman, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demeter, L. M.
Right arrow Articles by Reichman, R. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2000, p. 794-797, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

L. M. Demeter,1,* R. W. Shafer,2 P. M. Meehan,3 J. Holden-Wiltse,3 M. A. Fischl,4 W. W. Freimuth,5 M. F. Para,6 and R. C. Reichman1

University of Rochester School of Medicine and Dentistry, Rochester, New York1; Stanford University, Palo Alto, California2; Harvard School of Public Health, Boston, Massachusetts3; University of Miami, Miami, Florida4; Pharmacia and Upjohn, Kalamazoo, Michigan5; and Ohio State University, Columbus, Ohio6

Received 23 August 1999/Returned for modification 4 November 1999/Accepted 29 November 1999

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

* Corresponding author. Mailing address: University of Rochester Infectious Diseases Unit, 601 Elmwood Ave., Box 689, Rochester, NY 14642. Phone: (716) 275-4764. Fax: (716) 442-9328. E-mail: Lisa_Demeter{at}urmc.rochester.edu.

Antimicrobial Agents and Chemotherapy, March 2000, p. 794-797, Vol. 44, No. 3
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Herrera, C., Cranage, M., McGowan, I., Anton, P., Shattock, R. J. (2009). Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrob. Agents Chemother. 53: 1797-1807 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Joly, V., Descamps, D., Peytavin, G., Touati, F., Mentre, F., Duval, X., Delarue, S., Yeni, P., Brun-Vezinet, F. (2004). Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs. Antimicrob. Agents Chemother. 48: 172-175 [Abstract] [Full Text]  
  • Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M. (2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol. 77: 1512-1523 [Abstract] [Full Text]  
  • Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]  
  • Harrigan, P. R., Salim, M., Stammers, D. K., Wynhoven, B., Brumme, Z. L., McKenna, P., Larder, B., Kemp, S. D. (2002). A Mutation in the 3' Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. J. Virol. 76: 6836-6840 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Hermankova, M., Ray, S. C., Ruff, C., Powell-Davis, M., Ingersoll, R., D'Aquila, R. T., Quinn, T. C., Siliciano, J. D., Siliciano, R. F., Persaud, D. (2001). HIV-1 Drug Resistance Profiles in Children and Adults With Viral Load of <50 Copies/mL Receiving Combination Therapy. JAMA 286: 196-207 [Abstract] [Full Text]  
  • Bacheler, L., Jeffrey, S., Hanna, G., D'Aquila, R., Wallace, L., Logue, K., Cordova, B., Hertogs, K., Larder, B., Buckery, R., Baker, D., Gallagher, K., Scarnati, H., Tritch, R., Rizzo, C. (2001). Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy. J. Virol. 75: 4999-5008 [Abstract] [Full Text]  
  • Joly, V., Moroni, M., Concia, E., Lazzarin, A., Hirschel, B., Jost, J., Chiodo, F., Bentwich, Z., Love, W. C., Hawkins, D. A., Wilkins, E. G. L., Gatell, A. J., Vetter, N., Greenwald, C., Freimuth, W. W., de Cian, W., The M/3331/0013B Study Group, (2000). Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial. Antimicrob. Agents Chemother. 44: 3155-3157 [Abstract] [Full Text]  
  • Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A., Fay, P., Reichman, R. C., Bambara, R. A., Demeter, L. M. (2000). Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture. J. Virol. 74: 8390-8401 [Abstract] [Full Text]  
  • Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., Becker, M. F., Lasut, A. L., George, H. J., Spalding, D. R., Hollis, G., Abremski, K. (2000). Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy. Antimicrob. Agents Chemother. 44: 2475-2484 [Abstract] [Full Text]  
  • Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., Demeter, L. M., Vella, S., Jacobsen, D. M., Richman, D. D. (2000). Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel. JAMA 283: 2417-2426 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»